Lazertinib Mesylate

CHEMBL6068478 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

668.8 g/mol

LogP

—

Phase

4

A mesylate salt form of lazertinib, a third-generation EGFR inhibitor used to treat EGFR-mutated non-small cell lung cancer, formulated to improve solubility and absorption.

분자량

668.8000 g/mol

TPSA

173.00 Å²

작용 기전

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1.CS(=O)(=O)O.O

InChI

InChI=1S/C30H34N8O3.CH4O3S.H2O/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21;1-5(2,3)4;/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34);1H3,(H,2,3,4);1H2

Molecular Formula

C31H40N8O7S

HBD / HBA

4 / 13

회전 가능 결합

10

무거운 원자

47

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A mesylate salt form of lazertinib, a third-generation EGFR inhibitor used to treat EGFR-mutated non-small cell lung cancer, formulated to improve solubility and absorption.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Lazertinib Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068478. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 163203547. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Lazertinib Mesylate PillFYI에서

구조

핵심 데이터

분자식: C31H40N8O7S

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.